Introduction {#sec1}
============

E2F transcriptional factors implicated in the regulation of many cell possesses related to cellular proliferation, differentiation, DNA repair, cell-cycle and cell apoptosis \[[@B1],[@B2]\], and were critical components of the transcriptional machinery that modulates the expression of genes required for DNA synthesis and mitosis \[[@B3]\]. Members of the E2F transcription factor family have been shown to be overexpressed in many types of human malignancies \[[@B4]\].

As one of repressors in the E2F family, E2F8 has been shown to be a suppressive regulator of transcription and cell cycle progression \[[@B2],[@B5],[@B6]\]. In addition, atypical E2F8 showed suppress effects on tumor angiogenesis in three different cancer models \[[@B7]\]. Conversely, emerging evidence indicated that E2F8 might also be crucially involved in promotion of carcinogenesis. Oncogenic function and therapeutic value of E2F8 have been described in lung adenocarcinoma and squamous cell carcinoma. E2F8 is overexpressed in lung cancer and enhances cell proliferation, and depletion of E2F8 inhibited cell proliferation and tumor growth \[[@B8]\]. E2F8 up-regulation is associated with poor prognosis in lung cancer and ovarian cancer \[[@B8]\]. Hence, the functional effects of E2F8 in human cancers remain obscure.

Recent literatures demonstrated that E2F8 is strongly up-regulated in human hepatocellular carcinoma (HCC), showed to be tumor promoter to hepatocarcinogenesis \[[@B11]\]. Aberrant overexpression of E2F8 promoted cell proliferation, enhanced colony formation and contributed to tumorigenicity in HCC cells. Mechanism analysis revealed that E2F8 influences G1--S transition of cell cycle progression, promotes the entry of S phase and mediates cyclin D1 transcription in a dominant-negative manner \[[@B14]\]. In contrast, E2F7 and E2F8 synchronized deletion in hepatocytes leads to HCC \[[@B15]\]. Considered the controversial findings and its lack of clinical investigation, we conducted an integrated bioinformatic analysis to evaluate the expression, prognostic value and potential functional mechanism of E2F8 in HCC development.

Materials and methods {#sec2}
=====================

Microarray data of GEO, TCGA and Oncomine {#sec2-1}
-----------------------------------------

Microarray series of GSE45436, GSE55092, GSE60502, GSE84402, GSE33006, GSE74656 and GSE49515 were downloaded from GEO database (<https://www.ncbi.nlm.nih.gov/geo/>), the details of these GEO series were summarized in [Table 1](#T1){ref-type="table"}.

###### Details of GEO series included in this analysis

  GEO series   Contributor(s)         Tumor   Nontumor   Platform
  ------------ ---------------------- ------- ---------- --------------------------------------------------------------------------------
  GSE45436     Jui-Yu Hsieh, 2013     97      37         Affymetrix Human Genome U133 Plus 2.0 Array
  GSE55092     Patrizia Farci, 2014   49      91         Affymetrix Human Genome U133 Plus 2.0 Array
  GSE60502     KJ Kao, 2014           18      18         Affymetrix Human Genome U133A Array
  GSE84402     Zhuoan Cheng, 2016     14      14         Affymetrix Human Genome U133 Plus 2.0 Array
  GSE33006     Yi Huang, 2011         3       3          Affymetrix Human Genome U133 Plus 2.0 Array
  GSE74656     Huiyong Yin, 2015      5       5          GeneChip® PrimeView™ Human Gene Expression Array (with External spike-in RNAs)
  GSE49515     Kam Hui, 2013          10      10         Affymetrix Human Genome U133 Plus 2.0 Array

TCGA microarray data were obtained in R program using edgeR package \[[@B16]\]. Heatmap of E2F8 expression was performed in 50 paired tumor and nontumor samples using GraphPad prism v8.0 software (GraphPad Software, CA, U.S.A.).

Meta-analysis of E2F8 expression between HCC and normal liver tissues in Chen Liver \[[@B17]\] and Wurmbach Liver \[[@B18]\] were compared in Oncomine database. E2F8 levels with log2 median centered ratio in Chen Liver and Wurmbach Liver datasets were compared separately.

Survival analysis {#sec2-2}
-----------------

Survival analysis was performed in Kaplan--Meier plotter \[[@B19],[@B20]\], which integrated both gene expression and clinical data. Patient samples were divided into two groups by median cutoff of E2F8 (RNAseq ID: 79733) to analyze the prognostic value. Kaplan--Meier survival plot with the hazard ratio (HR) with 95% confidence intervals (CI) and log rank *P* value was calculated. Outcomes including overall survival (OS), recurrence-free survival (RFS), disease-specific survival (DSS) and progression-free survival (PFS) were investigated.

E2F8 expression comparison by clinico-pathological features {#sec2-3}
-----------------------------------------------------------

E2F8 expression data and clinical data of HCC patients in TCGA were downloaded from cBioPortal for Cancer Genomics \[[@B21],[@B22]\]. We matched the gene and clinical data using VLOOKUP index in EXCEL. When those without E2F8 expression data were excluded, 361 HCC patients were included in the final analysis. All these patients were divided into E2F8 high and E2F8 low expression groups using E2F8 median cutoff.

Enrichment analysis {#sec2-4}
-------------------

Protein--protein interaction of E2F8 was conducted in Search Tool for Retrieval of Interacting Genes/Proteins (STRING) online service \[[@B23]\]. Interacted genes of E2F8 were also identified in Search Tool for Interacting Chemicals (STITCH) database \[[@B24]\]. Top 20 similar genes of E2F8 were identified in Gene Expression Profiling Interactive Analysis (GEPIA) database \[[@B25]\]. All these interacted genes and similar genes of E2F8 in STRING, STITCH and GEPIA were included in the enrichment analysis in Gene Set Enrichment Analysis (GSEA) molecular signatures database \[[@B26],[@B27]\]. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, Gene ontology (GO) biological process and Reactome were enriched. Metascape web service was used to validate the GO enrichment terms \[[@B28]\].

Statistical analysis {#sec2-5}
--------------------

Student's *t* test or Mann--Whiney *U* test in GraphPad prism v8.0 (GraphPad Software, CA, U.S.A.) were performed to analyze the differences of gene expression. Factors associated with the survival were assessed by univariate analysis and multivariate analysis Cox regression. Only covariates significantly associated with outcomes at univariate analysis (two-sided *P* \<0.10) included in the multivariate model. Results were reported as HR with 95% CI. Stata software version 16.0 (Stata Corp LLC, Texas, U.S.A.) was used. A two tailed *P* \<0.05 was considered significant.

Results {#sec3}
=======

E2F8 expression comparison {#sec3-1}
--------------------------

In TCGA dataset, heatmap of E2F8 expression in 50 paired tumor and nontumor tissues was calculated, indicating that E2F8 was up-regulated in HCC tumors ([Figure 1](#F1){ref-type="fig"}A). As shown in [Figure 1](#F1){ref-type="fig"}B, E2F8 mRNA was significantly overexpressed in HCC tumors compared with that in nontumors (*P* \< 0.0001, [Figure 1](#F1){ref-type="fig"}B). Consistently, E2F8 mRNA was significantly up-regulated in tumor tissues than nontumors in 6 GEO series including GSE45436, GSE55092, GSE60502, GSE84402, GSE33006 and GSE74656 (all *P* \< 0.01, [Figure 1](#F1){ref-type="fig"}C). Additionally, E2F8 mRNA was also significantly elevated in serum peripheral blood mononuclear cell (PBMC) in HCC patients than that in healthy individuals (*P* \< 0.001, [Figure 1](#F1){ref-type="fig"}D).

![E2F8 expression in hepatocellular carcinoma\
(**A**) Heatmap of E2F8 mRNA expression in 50 paired tumor and nontumor tissues in TCGA dataset. (**B**) E2F8 mRNA expression in tumor and nontumor tissues in TCGA dataset. (**C**) E2F8 mRNA expression in tumor and nontumor tissues in GEO series. (**D**) E2F8 mRNA expression in serum PBMC in healthy individuals and HCC patients. \*\**P*\<0.01; \*\*\**P*\<0.001; and \*\*\*\**P*\<0.0001.](bsr-40-bsr20193212-g1){#F1}

Meta-analysis of two studies in Oncomine database confirmed that E2F8 was significantly higher in HCC tumors and normal livers (*P* = 4.28E-08, [Figure 2](#F2){ref-type="fig"}A). Separately, E2F8 mRNA was significantly overexpressed in HCC tissues than normal liver tissues in Chen Liver and Wurmbach Liver (both *P* \< 0.0001, [Figure 2](#F2){ref-type="fig"}B,C).

![Meta-analysis of E2F8 mRNA expression in Oncomine database\
(**A**) Meta-analysis of E2F8 mRNA expression in two studies including Chen Liver and Wurmbach Liver in Oncomine. (**B**) E2F8 expression in normal liver and HCC in Chen Liver. (**C**) E2F8 expression in normal liver and HCC in Wurmbach Liver.](bsr-40-bsr20193212-g2){#F2}

OS, RFS, DSS and PFS in E2F8 high and low groups {#sec3-2}
------------------------------------------------

As shown in [Figure 3](#F3){ref-type="fig"}, E2F8 high expression was significantly correlated with poor OS (HR = 1.99, 95%CI = 1.4--2.84, *P* = 1E-04, [Figure 3](#F3){ref-type="fig"}A), and same trends were observed when comparing 1-, 3- and 5-year OS in HCC patients (HR = 3.34, *P* = 3.3E-05; HR = 2.74, *P* = 1E-06 and HR = 2.14, *P* = 4.1E-05, respectively, [Figure 3](#F3){ref-type="fig"}B--D). In addition, E2F8 overexpression was significantly associated with worse RFS in HCC patients (HR = 1.68, 95%CI = 1.2--2.34, *P* = 0.0021, [Figure 3](#F3){ref-type="fig"}E). Also, E2F8 high level contributed to 1-year recurrence, 3-year recurrence and 5-year recurrence in HCC patients (HR = 2.33, *P* = 9.7E-05; HR = 1.74, *P* = 0.0017 and HR = 1.7, *P* = 0.0017, respectively, [Figure 3](#F3){ref-type="fig"}F--H).

![Correlation between E2F8 and overall survival (OS) and recurrence-free survival (RFS) in HCC patients\
(**A**) Overall survival, (**B**) 1-year OS, (**C**) 3-year OS and (**D**) 5-year OS for HCC patients grouped by E2F8 expression with median cutoff. (**E**) Recurrence-free survival, (**F**) 1-year RFS, (**G**) 3-year RFS and (**H**) 5-year RFS for HCC patients grouped by E2F8 expression with median cutoff.](bsr-40-bsr20193212-g3){#F3}

Moreover, up-regulation of E2F8 was significantly associated with DSS, 1-, 3- and 5-year DSS in HCC patients (HR = 2.76, *P* = 1.3E-05; HR = 7.49, *P* = 0.00013; HR = 5.29, *P* = 2.4E-08 and HR = 2.92, *P* = 1.1E-05, respectively, [Figure 4](#F4){ref-type="fig"}A--D). HCC patients with high E2F8 levels had poor PFS, 1-, 3- and 5-year PFS compared with those in E2F8 low expression group (HR = 1.93, *P* = 1E-05; HR = 2.62, *P* = 5.7E-07; HR = 2.01, *P* = 8.4E-06 and HR = 1.92, *P* = 1.3E-05, respectively, [Figure 4](#F4){ref-type="fig"}E--H).

![Correlation between E2F8 and disease-specific survival (DSS) and progression-free survival (PFS) in HCC patients\
(**A**) Disease-specific survival, (**B**) 1-year DSS, (**C**) 3-year DSS and (**D**) 5-year DSS for HCC patients grouped by E2F8 expression with median cutoff. (**E**) Progression-free survival, (**F**) 1-year PFS, (**G**) 3-year PFS and (**H**) 5-year PFS for HCC patients grouped by E2F8 expression with median cutoff.](bsr-40-bsr20193212-g4){#F4}

Associations between E2F8 and OS and DFS in HCC patients {#sec3-3}
--------------------------------------------------------

Based on liver hepatocellular carcinoma (TCGA, Provisional) profile in cBioPortal for Cancer Genomics, Cox regression model was used to identify the potential risk factors for OS and DFS in HCC patients. Variables including E2F8, gender, body mass index, race, tumor status, family history of cancer, pathological grade, AJCC stage, vascular invasion, AFP, new tumor event after initial treatment and hepatic inflammation were included in the univariate analysis. As summarized in [Table 2](#T2){ref-type="table"}, univariate analysis showed that E2F8, tumor status, AJCC stage and new tumor event after initial treatment were potential risk factors of OS in HCC patients (all *P* \< 0.1, [Table 2](#T2){ref-type="table"}). After adjusting tumor status, AJCC stage and new tumor event after initial treatment in multivariate Cox regression model, high level of E2F8 showed to be an independent risk factor for OS in HCC patients (HR = 2.16, 95%CI = 1.3--3.59, *P* = 0.003, [Table 2](#T2){ref-type="table"}).

###### Univariate and multivariate Cox regression analysis of parameters associated with OS and DFS in HCC patients[^\#^](#T2TFN1){ref-type="table-fn"}

  Variables                                                OS                  DFS                                                                                          
  -------------------------------------------------------- ------------------- --------- -------------------- --------- -------------------- --------- -------------------- ---------
  E2F8, high versus low                                    1.98 (1.39--2.83)   \<0.001   2.16 (1.3--3.59)     0.003     1.87 (1.38--2.54)    \<0.001   1.64 (1.19--2.25)    0.002
  Tumor status, with tumor versus tumor free               1.59 (1.11--2.28)   0.012     2.14 (0.92-- 4.95)   0.076     3.71 (2.7--5.09)     \<0.001   3.65 (2.64 --5.05)   \<0.001
  AJCC stage                                                                                                                                                                
    I                                                      Reference           1.0       Reference            1.0       Reference            1.0       Reference            1.0
    II                                                     1.49 (0.91--2.44)   0.111     1.79 (0.9--3.59)     0.098     2.03 (1.36-- 3.03)   0.001     1.92 (1.26--2.91)    0.002
    III                                                    2.82 (1.85--4.28)   \<0.001   4.05 (2.27--7.25)    \<0.001   3.05 (2.11-- 4.4)    \<0.001   2.96 (2.02-- 4.33)   \<0.001
    IV                                                     2.64 (1.38--5.04)   0.003     2.9 (0.85--9.85)     0.088     2.07 (1.11--3.85)    0.022     1.28 (0.67--2.47)    0.454
  New tumor event after initial treatment, Yes versus No   1.52 (0.95--2.42)   0.081     0.94 (0.41--2.2)     0.895     --                   --        --                   --

Variables including E2F8, gender, body mass index, race, tumor status, family history of cancer, pathological grade, AJCC stage, vascular invasion, AFP, new tumor event after initial treatment and hepatic inflammation were included in the univariate analysis. Only variables with *P* \< 0.10 in univariate model were included in the multivariate analysis.

Only variables significantly associated with OS/DFS in univariate analysis were presented.

Moreover, E2F8, tumor status and AJCC stage were identified as potential risk factors of DFS in HCC patients (all *P* \< 0.1, [Table 2](#T2){ref-type="table"}). After adjusting tumor status and AJCC stage in multivariate Cox regression model, high level of E2F8 showed to be an independent risk factor for DFS in HCC patients (HR = 1.64, 95%CI = 1.19--2.25, *P* = 0.002, [Table 2](#T2){ref-type="table"}).

Correlations between E2F8 and clinico-pathological features in HCC {#sec3-4}
------------------------------------------------------------------

E2F8 genetic alteration was observed in 5% of all HCC participants in TCGA Pan-Cancer Atlas ([Figure 5](#F5){ref-type="fig"}A). Heatmap of E2F8 expression in HCC tumors was also presented in [Figure 5](#F5){ref-type="fig"}A. As shown in [Figure 5](#F5){ref-type="fig"}B, E2F8 mRNA was significantly higher in HCC patients with advanced neoplasm grade, AJCC stage and α-fetoprotein elevation (all *P* \< 0.05, [Figure 5](#F5){ref-type="fig"}B).

![E2F8 expression heatmap and E2F8 levels by clinico-pathological features in HCC tumors\
(**A**) Heatmap of E2F8 mRNA in HCC samples in TCGA from cBioPortal; (**B**) E2F8 mRNA expression comparison by clinico-pathological features including neoplasm histologic grade, AJCC stage and AFP level. \**P*\<0.05; \*\**P*\<0.01.](bsr-40-bsr20193212-g5){#F5}

Interacted genes and enrichment of E2F8 {#sec3-5}
---------------------------------------

E2F1, CDCA8, DLGAP5, KIF11, TOPA2, TP53, BUB1B, E2F7, RRM2 and CCNA2 were interacted with E2F8 in STRING database ([Figure 6](#F6){ref-type="fig"}A), while TFDP3, TFDP1, E2F7, TP53, RBL1, RBL2, RB1, CDC6, E2F6 and CCNA2 were interacted with E2F8 in STITCH database ([Figure 6](#F6){ref-type="fig"}B). Top 20 similar genes of E2F8 in HCC tumors in GEPIA database were identified ([Figure 6](#F6){ref-type="fig"}C). In GSEA database, KEGG pathway, GO biological process and Reactome enrichment revealed that most genes were enriched in cell cycle pathway/biological process, mainly functioned in G and S phases ([Figure 6](#F6){ref-type="fig"}D). In addition, these interacted genes of E2F8 also related with many types of human malignancies including bladder cancer, non-small cell lung cancer, glioma, pancreatic cancer, melanoma, chronic myeloid leukemia, small cell lung cancer and prostate cancer ([Figure 6](#F6){ref-type="fig"}D). For enrichment validation, Metascape web service was used. Consistent with results from GSEA enrichment, enrichment heatmap demonstrated that most interacted genes or similar genes of E2F8 were involved in cell cycle regulation ([Figure 6](#F6){ref-type="fig"}E).

![Interacted genes of E2F8 and functional enrichment\
(**A**) Protein--protein interaction of E2F8 in STRING. (**B**) Interacted genes with E2F8 in STITCH. (**C**) Similar genes of E2F8 in HCC tumors by GEPIA. (**D**) KEGG pathway, biological process (GO) and Reactome enrichment of interacted/similar genes with E2F8 and (**E**) Bar heatmap of enriched terms of E2F8 in Metascape.](bsr-40-bsr20193212-g6){#F6}

Discussion {#sec4}
==========

E2F8 has been reported to overexpress in lung cancer, breast cancer, colorectal cancer, ovarian cancer, prostate cancer, esophageal squamous cell carcinoma and HCC \[[@B8],[@B29]\]. Consistently, our results also indicated that E2F8 was up-regulated in HCC tumors and correlated with advanced tumor stage and AFP elevation. However, opposite phenomenon of cellular proliferation of E2F8 in human cancers has been reported. The ectopic E2F8 expression contributes to the suppress of E2F-targeted gene expression and slows down the proliferation of mouse embryonic fibroblasts and stress-induced skin cancer \[[@B6],[@B34]\], while E2F8 overexpression promotes cell proliferation and tumorigenesis in many types of cancers including esophageal squamous cell carcinoma, papillary thyroid cancer, prostate cancer, lung cancer and liver cancer \[[@B8],[@B14],[@B31],[@B32],[@B35]\]. That is E2F8 might function as a transcriptional repressor or activator in cell cycle progression, even in liver development \[[@B14],[@B15]\]. In HCC, considered previous evidence \[[@B36],[@B37]\] and our findings, we cautiously drew hypothesis that E2F8 exerts pro-oncogenic effects in HCC progression.

Currently, the clinical significance of E2F8 in HCC aggressiveness has not yet been elucidated. Moreover, contradictory results of E2F8 in HCC tumorigenesis have been reported. Kent et al. reported that combined deletion of E2F7 and E2F8 in hepatocytes leads to HCC. Temporal-specific ablation strategies recovered that E2F8 exerts tumor suppressor effects in postnatal liver development during the first 2 weeks of life \[[@B15]\]. Conversely, aberrant up-regulation of E2F8 promoted cell proliferation, colony formation and tumorigenicity, while E2F8 knockdown suppressed these phenotypes in HCC cell lines \[[@B14]\]. E2F8 overexpression in HCC facilitated the tumor occurrence and aggressiveness through activating a E2F1/Cyclin D1 signaling pathway to regulate the G1-S transition or transcriptionally suppressing CDK1 to induce hepatocyte polyploidization. Previous evidence demonstrated that E2F8 involved closely in a variety of cellular physiological functions and pathological processes including cell cycle, cell proliferation, cell survival, DNA damage, angiogenesis, lymphangiogenesis and cell polyploidization in HCC \[[@B14],[@B36]\]. Our enrichment analysis revealed that E2F8 and its related genes were mainly involved in regulation of cell cycle. Unfortunately, we could not conduct experimental research for investigating the oncogenic mechanisms of E2F8 in HCC. Oncogenic mechanisms of E2F8 in hepatoma cell cycle need further experimental confirmation.

In our analysis, we found that overexpression of E2F8 contributed to poor survivals in HCC, including OS, RFS, PFS and DSS. Cox hazard regression model revealed that high level of E2F8 should be an independent risk factor for OS and DFS in HCC patients. Lee et al. reported that increased expression of E2F8 is associated with prostate cancer metastasis and correlated to worse OS in prostate cancer patients \[[@B31]\]. In ovarian cancer, E2F8 expression levels were significantly elevated in patients with residual disease \>2 cm in diameter, and E2F8 down-regulation yielded longer OS \[[@B9]\]. Additionally, poorer OS in non-small cell lung cancer patients with E2F8 overexpression has been observed than in those without \[[@B10]\]. While no significances of RFS were found both in ovarian cancer and lung cancer \[[@B9],[@B10]\]. Taken together, our findings strengthened the evidence that increased E2F8 in tumors accounted for poor prognosis in HCC patients.

Intriguingly, sharp opposite results of E2F8 also have been identified in angiogenesis. Weijts et al. reported that E2F8 is essential for blood vessel formation and its deletion results in vascular defects in zebrafish and mice. Molecular mechanism demonstrated that E2F8 increased the activation of the transcription of the vascular endothelial growth factor A (VEGFA). In contrast, E2F8 deficient skin tumors displayed enhanced angiogenesis, and E2F8 inhibited tumor angiogenesis in a xenograft model for sarcomas driven by Myc and Ras oncogenes and suppressed intratumoral vessel hyperbranching via induction of delta-like ligand 4 \[[@B7]\].

Although the controversial effects of E2F8 existed in regulation of cell cycle progression and tumor angiogenesis, our findings supported the conclusion that E2F8 was overexpressed in tumors, correlated with advanced tumor stage and high AFP level, and poor survivals in HCC patients, indicating that E2F8 should be a potential therapeutic target for HCC treatment \[[@B36]\].
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